Scientific Reports (Aug 2023)

Exploring the therapeutic potential of an antinociceptive and anti-inflammatory peptide from wasp venom

  • Priscilla Galante,
  • Gabriel A. A. Campos,
  • Jacqueline C. G. Moser,
  • Danubia B. Martins,
  • Marcia P. dos Santos Cabrera,
  • Marisa Rangel,
  • Luiza C. Coelho,
  • Karina S. Simon,
  • Veronica M. Amado,
  • Jessica de A. I. Muller,
  • Johannes Koehbach,
  • Rink-Jan Lohman,
  • Peter J. Cabot,
  • Irina Vetter,
  • David J. Craik,
  • Monica C. Toffoli-Kadri,
  • Victoria Monge-Fuentes,
  • Jair T. Goulart,
  • Elisabeth F. Schwartz,
  • Luciano P. Silva,
  • Anamelia L. Bocca,
  • Márcia R. Mortari

DOI
https://doi.org/10.1038/s41598-023-38828-w
Journal volume & issue
Vol. 13, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Animal venoms are rich sources of neuroactive compounds, including anti-inflammatory, antiepileptic, and antinociceptive molecules. Our study identified a protonectin peptide from the wasp Parachartergus fraternus' venom using mass spectrometry and cDNA library construction. Using this peptide as a template, we designed a new peptide, protonectin-F, which exhibited higher antinociceptive activity and less motor impairment compared to protonectin. In drug interaction experiments with naloxone and AM251, Protonectin-F's activity was decreased by opioid and cannabinoid antagonism, two critical antinociception pathways. Further experiments revealed that this effect is most likely not induced by direct action on receptors but by activation of the descending pain control pathway. We noted that protonectin-F induced less tolerance in mice after repeated administration than morphine. Protonectin-F was also able to decrease TNF-α production in vitro and modulate the inflammatory response, which can further contribute to its antinociceptive activity. These findings suggest that protonectin-F may be a potential molecule for developing drugs to treat pain disorders with fewer adverse effects. Our results reinforce the biotechnological importance of animal venom for developing new molecules of clinical interest.